Zhang, Rohweder et al report that covalent K-Ras(G12C) inhibitors can lead to the presentation of drug-modified neoantigens by class I MHC. A bispecific T cell engager that recognizes these neoantigens elicits a cytotoxic T cell response against KRas G12C cells, including those resistant to direct KRasG12C inhibition.
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity
William A. Freed-Pastor, Andrew J. Aguirre - Cancer Cell Preview
Featured Articles and Interviews
Closing in on Cancer's Deadliest Mutations - nature Feature Article
Developing A Drug To Identify And Target Tricky Cancer Cells - Discover Magazine
Drug Turns Cancer Gene Into “Eat Me” Flag for Immune System - UCSF News
KGO810 The Pat Thurston Show - Charles Craik interview - Stitcher Apple Podcast
The epic battle with cancer's 'Death Star' - The Guardian
Ziyang Zhang - Chemical biology champion is toppling drug targets with novel approaches - c&en
Kevan Shokat interviewed "Drugging the undruggable" - Disease Models and Mechanisms on YouTube
Patent Cooperation Treaty (PCT) filing - Patentscope